Antineuoplastic agents include- Interferon ALFA 2a, Interferon ALFA -2b, Interferon ALFA -n3, Levamisole, Altretamine, Cladribine, Hydroxyurea, Aldesleukin, Paclitaxel, Docetaxel,Tretinion, Procarbazine,Dacarbazine, Gemcitabine, Mitotane, Asparaginase, Pegaspargase,Porfimer Sodium

In vitro studies have shown that the metabolism of docetaxel may be modified by concomittant administration of compounds that may induce , inhibit or are metabolised by P4502AA, such as terfenadrine, ketoconazole. erythromycin and troleandomycin.

U.S FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08

Hypotension, Atrial fibrillation, Deep vein thrombosis, ECG abnormalities, Thrombophlebitis, Pulmonary embolism, Syncope, Tachycardia, Heart failure, Sinus tachycardia. Constipation, Ulcer. Dyspnea, Acute pulomonary edema. Abdominal pain, Diffuse pain, Chest pain, Confusion, Renal insufficiency.

Hyersens sensitivity to the drug.

Special precautions:

Monitoring occurance of mylotoxicity. neuologic symptoms.

Asthenia - severe caes reported

Approved by FDA on May 14, 1996

Indicatons: Breast cancer

Dosage:

Recommended dose is 60 to 100mg/m2 administered IV over 1 hour every 3 weeks

Pharmacology:

Doxetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of the yew plant.

Pharmacokinetics:

Docetaxel is eliminated in both urine and feces following oxidative metabolism of tert-butyl ester group.

Pregnancy:

Advise woman of child bearing potential to avoid pregnancy during therapy.

Lactation-

Mothers should discontinue nursing prior to taking the drug.